Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Cyclerion Therapeutics Inc chart...

About the Company

cyclerion therapeutics, inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. its product candidates include olinciguat, an orally administered vascular soluble guanylate cyclase (sgc) stimulator that is in phase ii studies for the treatment of sickle cell disease (scd); praliciguat, an orally administered systemic sgc stimulator that is in phase ii trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and iw-6463, an orally administered central nervous system (cns)-penetrant sgc stimulator, which is in phase i trials for neurodegenerative diseases. the company is also discovering liver-targeted sgc and lung-targeted sgc stimulators. cyclerion therapeutics, inc. was incorporated in 2018 and is headquartered in cambridge, massachusetts.

Exchange

NASDAQ

$0M

Total Revenue

35

Employees

$8M

Market Capitalization

8.28

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CYCN News

Cyclerion Therapeutics Inc Ordinary Shares

18d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company

29d ago, source: ADVFN

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company acting solely by all of its independent and disinterested members (the “Independent Board ...

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

1mon ago, source: ADVFN

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a biopharmaceutical company on a mission to develop treatments for serious diseases, today announced the appointments of Dina Katabi, Ph.D., and ...

CVKD Cadrenal Therapeutics, Inc.

4d ago, source: Seeking Alpha

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart ...

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript

19d ago, source: Yahoo Finance

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript February 28, 2024 G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27.

KROS Keros Therapeutics, Inc.

5d ago, source: Seeking Alpha

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the ...

Cyclerion Therapeutics, Inc. (CYCN)

4d ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Cyclerion Therapeutics Inc (CYCN)

11d ago, source: Investing

Investing.com – U.S. stocks were higher after the close on Wednesday, as gains in the Oil & Gas, Technology and Telecoms sectors led shares higher. At the close in NYSE, the Dow ...

Cyclerion Therapeutics Inc (CYCN)

14d ago, source: Investing

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) reported fourth-quarter 2019 adjusted earnings of 30 cents per share, surpassing the Zacks Consensus Estimate of 22 cents. Earnings ...

Cyclerion Therapeutics, Inc. (CYCN)

13d ago, source: Yahoo Finance

*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...